5:57 PM
 | 
Oct 17, 2012
 |  BC Extra  |  Top Story

FDA panel backs Aegerion's lomitapide

FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 13-2 that efficacy and safety data for lomitapide from Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) support approval to treat homozygous familial hypercholesterolemia (hoFH). Aegerion agreed to conduct a long-term postmarketing observational study of lomitapide that would monitor...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >